Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 0.12% and Operating profit at -4.23% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 8.29% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 0.12% and Operating profit at -4.23% over the last 5 years
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROE of 8.44%, it has a fair valuation with a 0.79 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Chemicals & Petrochemicals
CNY 8,477 Million (Mid Cap)
9.00
NA
10.51%
0.37
8.44%
0.82
Revenue and Profits:
Net Sales:
3,091 Million
(Quarterly Results - Jun 2026)
Net Profit:
286 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.55%
0%
4.55%
6 Months
-9.34%
0%
-9.34%
1 Year
-2.24%
0%
-2.24%
2 Years
10.35%
0%
10.35%
3 Years
-13.64%
0%
-13.64%
4 Years
-19.67%
0%
-19.67%
5 Years
-49.6%
0%
-49.6%
Huapont Life Sciences Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.12%
EBIT Growth (5y)
-4.23%
EBIT to Interest (avg)
2.99
Debt to EBITDA (avg)
2.63
Net Debt to Equity (avg)
0.62
Sales to Capital Employed (avg)
0.59
Tax Ratio
17.93%
Dividend Payout Ratio
124.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.44%
ROE (avg)
8.29%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.76
EV to EBIT
9.72
EV to EBITDA
5.46
EV to Capital Employed
0.82
EV to Sales
1.02
PEG Ratio
0.02
Dividend Yield
11.30%
ROCE (Latest)
8.47%
ROE (Latest)
8.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
3,091.20
2,818.70
9.67%
Operating Profit (PBDIT) excl Other Income
696.40
635.80
9.53%
Interest
57.60
55.40
3.97%
Exceptional Items
-2.20
-1.80
-22.22%
Consolidate Net Profit
286.20
240.90
18.80%
Operating Profit Margin (Excl OI)
136.80%
128.60%
0.82%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 9.67% vs 16.17% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 18.80% vs 13,283.33% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
11,464.70
11,621.80
-1.35%
Operating Profit (PBDIT) excl Other Income
2,509.10
2,094.50
19.79%
Interest
324.60
369.50
-12.15%
Exceptional Items
-103.20
-819.20
87.40%
Consolidate Net Profit
881.20
-342.60
357.21%
Operating Profit Margin (Excl OI)
111.80%
89.40%
2.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.35% vs 0.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 357.21% vs -150.61% in Dec 2024
About Huapont Life Sciences Co., Ltd. 
Huapont Life Sciences Co., Ltd.
Chemicals & Petrochemicals
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






